Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

অনুরূপ উপাদানগুলি

• Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
  অনুযায়ী: Marin, David, অন্যান্য
  প্রকাশিত: (2010)
• Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
  অনুযায়ী: Ibrahim, Amr R., অন্যান্য
  প্রকাশিত: (2010)
• Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response
  অনুযায়ী: Kuwabara, Aya, অন্যান্য
  প্রকাশিত: (2010)
• Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
  অনুযায়ী: Milojkovic, Dragana, অন্যান্য
  প্রকাশিত: (2012)
• Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
  অনুযায়ী: Nteliopoulos, Georgios, অন্যান্য
  প্রকাশিত: (2019)